Cardiometabolic & Bone

Cat. No.

AT0667

CAS No.

1446419-85-7

Evinacumab

Synonyms: REGN1500

Evinacumab (REGN1500) is a human monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3) and belongs to the IgG4 subclass. This antibody effectively reduces plasma lipid levels by inhibiting the activity of ANGPTL3. It has demonstrated efficacy in preclinical models, specifically in dyslipidemic mice, showcasing its potential in lipid metabolism regulation. Evinacumab is applicable for research in various lipid disorders, including homozygous familial hypercholesterolemia (HoFH), refractory hypercholesterolemia (both familial and non-familial), and severe hypertriglyceridemia, providing a valuable tool for studies in lipid regulation and cardiovascular disease.

Cat. No.

AT0669

CAS No.

1256937-27-5

Evolocumab

Synonyms: AMG 145

Evolocumab (AMG 145) is a human monoclonal antibody specifically designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is extensively utilized in research focused on hypercholesterolemia and atherosclerotic cardiovascular disease due to its unique mechanism of action. Evolocumab effectively binds to the circulating PCSK9 protein, preventing its interaction with the low-density lipoprotein receptor (LDLR), thereby facilitating the maintenance of LDLR levels on hepatocyte surfaces and promoting LDL clearance. Additionally, Evolocumab exhibits antioxidant and cytoprotective properties, offering protection against H₂O₂-induced oxidative damage in endothelial cells. This is particularly relevant in studies exploring endothelial function under oxidative stress conditions. Furthermore, preliminary evidence suggests that Evolocumab may inhibit the activation of the TLR-4/NF-κB signaling pathway, potentially reducing inflammatory responses, which is crucial in the context of cardiovascular diseases. This multifaceted biological activity makes Evolocumab a valuable tool in cardiovascular research, particularly in the investigation of mechanisms underlying lipid metabolism and inflammation.

Cat. No.

AT0690

Anti-INHBB/Activin B Antibody

The Anti-INHBB/Activin B Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting INHBB/Activin B. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is ideal for research applications focusing on the biological functions and regulatory mechanisms of INHBB/Activin B.

Cat. No.

AT0707

CAS No.

1233956-13-2

Volagidemab

Synonyms: REMD-477; AMG-477

Volagidemab is a monoclonal antibody designed to act as an antagonist to the glucagon receptor (GCGR). This antibody is specifically developed for use in research focused on Type 1 Diabetes (T1D), providing a critical tool for investigating the role of GCGR in glucose regulation and diabetic pathology.

Cat. No.

AT0741

CAS No.

1132758-87-2

Blosozumab

Blosozumab (LY2541546) is a monoclonal antibody that targets human sclerostin (SOST), functioning as an inhibitor. This antibody promotes bone formation while concurrently decreasing bone resorption, making it a valuable tool in osteoporosis research. Blosozumab is specifically designed to elucidate the pathways and potential therapeutic effects related to bone density regulation and osteoporotic condition management.

Cat. No.

AT0757

CAS No.

2566473-71-8

Prafnosbart

Synonyms: DS-6016A

Prafnosbart (DS-6016A) is a humanized monoclonal antibody of the IgG1-kappa isotype, targeting ACVR1 (also known as activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1). This antibody is specifically designed for the study of bone metabolism disorders, providing a crucial tool for researchers investigating the signaling pathways and regulatory mechanisms involved in bone development and maintenance.

Cat. No.

AT0772

CAS No.

2965214-50-8

Cliramitug

Cliramitug is a monoclonal antibody that specifically targets human transthyretin (TTR). This antibody interacts with TTR, effectively inhibiting its propensity to form amyloid fibrils. By preventing amyloidogenesis, Cliramitug serves as a valuable tool in the study of transthyretin amyloidosis and its associated neurological and cardiovascular pathologies. This antibody is instrumental for researchers focusing on the molecular mechanisms and therapeutic interventions for TTR-related diseases.

Cat. No.

AT0786

CAS No.

1610833-03-8

Burosumab

Synonyms: KRN23

Burosumab is a human monoclonal antibody that selectively neutralizes fibroblast growth factor 23 (FGF23). This antibody is employed in the study of disorders such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia, offering significant insights into the pathophysiological mechanisms and potential therapeutic targets for these conditions.

Cat. No.

AT0794

CAS No.

909395-70-6

Romosozumab

Romosozumab is a humanized monoclonal antibody that targets sclerostin, a protein involved in the regulation of bone metabolism. By inhibiting sclerostin, Romosozumab enhances bone formation and decreases bone resorption, making it a valuable tool for investigating the pathophysiology and potential treatments of osteoporosis. This antibody is specifically designed for use in research applications focused on bone density disorders and related metabolic bone diseases.

Cat. No.

AT0968

CAS No.

2145096-91-7

Ongericimab

Synonyms: JS002

Ongericimab (JS002) is a humanized monoclonal antibody targeting PCSK9, designed to effectively lower lipid levels. This antibody is specifically developed for research applications focusing on hypercholesterolemia and hyperlipidemia, providing a valuable tool for investigating the regulation of cholesterol metabolism and assessing potential therapeutic strategies for lipid disorders.

Cat. No.

AT1005

RG-7652

Anti-PCSK9 (RG7652) is a fully human monoclonal antibody of the immunoglobulin G1 (IgG1) subclass, designed to specifically target proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody has demonstrated potential efficacy in reducing the risk associated with coronary heart disease (CHD) by modulating lipid metabolism through the inhibition of PCSK9, a key regulator of cholesterol homeostasis. Anti-PCSK9 (RG7652) is suitable for use in research focused on lipid disorders, cardiovascular diseases, and the molecular mechanisms of cholesterol regulation.

Cat. No.

AT1033

CAS No.

1629605-31-7

Domagrozumab

Synonyms: PF-06252616

Domagrozumab is a humanized monoclonal antibody that targets myostatin with a dissociation constant (K_D) of 2.6 pM, indicating high affinity binding. By inhibiting myostatin, a negative regulator of muscle growth, Domagrozumab promotes anabolic activity in muscle tissues. This antibody is primarily utilized in research focused on Duchenne Muscular Dystrophy (DMD), providing a valuable tool for studying the pathology and potential therapeutic interventions for this condition.

Cat. No.

AT1062

CAS No.

1643672-70-1

Frovocimab

Synonyms: LY 3015014

Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody designed to neutralize proprotein convertase subtilisin/kexin type 9 (PCSK9). By inhibiting the interaction between PCSK9 and the low-density lipoprotein receptor (LDLR), Frovocimab facilitates the normal proteolytic processing of PCSK9 without disrupting its binding, thereby maintaining cholesterol homeostasis. This antibody is pivotal for research focused on lipid metabolism and cardiovascular diseases, offering potential insights into the regulation of cholesterol levels and the mechanisms of atherosclerosis.

Cat. No.

AT1076

CAS No.

2278276-46-1

Apitegromab

Synonyms: SRK-015

Apitegromab (SRK-015) is a monoclonal antibody targeting promyostatin. This biologic is specifically designed for the investigation of neuromuscular disorders, including spinal muscular atrophy. Apitegromab's mechanism involves modulating the activity of promyostatin, a key regulator in muscle development and growth, making it a valuable tool in research focused on muscle pathology and therapeutic development.

Cat. No.

AT1079

CAS No.

1391726-30-9

Landogrozumab

Synonyms: LY2495655; Anti-GDF8 / Myostatin Reference Antibody (landogrozumab

Landogrozumab (LY2495655) is a humanized monoclonal antibody targeting myostatin, a protein known to inhibit muscle growth. By neutralizing myostatin, Landogrozumab has been shown to enhance muscle volume, hand grip strength, and overall muscle function. This antibody is primarily utilized in research focused on muscle wasting diseases, providing a valuable tool for investigating potential therapeutic interventions for conditions characterized by muscle degeneration and loss.

Cat. No.

AT1102

CAS No.

1847394-95-9

Setrusumab

Synonyms: BPS 804

Setrusumab (BPS 804) is a fully human monoclonal antibody that specifically targets sclerostin, a protein involved in the negative regulation of bone formation. By inhibiting sclerostin, Setrusumab enhances bone formation and improves bone strength. This antibody is primarily utilized in research focused on Osteogenesis Imperfecta (OI) and various cancer models where bone density and strength are of interest. Setrusumab offers a valuable tool for researchers studying the pathophysiology and potential therapeutic interventions for disorders associated with compromised bone integrity.

Cat. No.

AT1127

CAS No.

2646587-68-8

Narlumosbart

Narlumosbart (JMT103) is a monoclonal antibody of the IgG4κ subtype designed to specifically target the receptor activator of nuclear factor-κB ligand (RANKL). This antibody is engineered to interact with RANKL, a critical mediator in the regulation of bone metabolism, immune interactions, and the development of lymphoid tissues. Narlumosbart is utilized primarily in research focused on bone diseases, immune system disorders, and cancer metastasis to bone.

Cat. No.

AT1130

CAS No.

2626841-92-5

Coramitug

Coramitug is a human IgG1 κ monoclonal antibody targeting transthyretin (TTR). For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

Cat. No.

AT1143

CAS No.

705287-60-1

Stamulumab

Synonyms: MYO-029

Stamulumab (MYO-029) is a recombinant human IgG1λ antibody designed to selectively bind to myostatin, effectively neutralizing its activity. This inhibition is achieved by preventing myostatin from interacting with its high-affinity receptor, ActRIIB. The primary biological outcome observed with Stamulumab treatment is muscle fiber hypertrophy, rather than hyperplasia, as demonstrated in SCID mice studies. Given its mechanism of action, Stamulumab is a valuable tool for research into various muscular dystrophies, including Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD), offering potential insights into therapeutic strategies targeting muscle growth and repair.

Cat. No.

AT1156

NGM-120

NGM-120 is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Glial Cell line-Derived Neurotrophic Factor Family Receptor Alpha Like (GFRAL). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145.7 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT1183

CAS No.

1355338-54-3

Lodelcizumab

Lodelcizumab is a monoclonal antibody that specifically targets proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is utilized in research settings to investigate the biological mechanisms and potential therapeutic interventions for hypercholesterolemia. Lodelcizumab binds to PCSK9, inhibiting its function, which is crucial in the regulation of cholesterol levels in the bloodstream. This makes it a valuable tool for studies focused on lipid metabolism and cardiovascular disease.

Cat. No.

AT1209

CAS No.

2653183-66-3

Delpacibart

Delpacibart is a humanized IgG1κ monoclonal antibody specifically designed to target the transferrin receptor (TFRC). TFRC is a critical membrane protein that plays a pivotal role in regulating intracellular iron transport. This antibody is instrumental in studies focusing on iron metabolism and related cellular processes.

Cat. No.

AT1296

CAS No.

2095467-30-2

Rolinsatamab

Rolinsatamab is a chimeric monoclonal antibody of the IgG1κ subtype, specifically designed to target the prolactin receptor (PRLR). This antibody can be conjugated to the pyrrolobenzodiazepine (PDB) dimer SGD-1882 through a cleavable maleimidocaproyl linker, creating the antibody-drug conjugate known as Rolinsatamab talirine. This conjugate features an average of two site-specific drug attachments at engineered cysteines (S239C). The linker incorporates a valine-alanine dipeptide, which serves as a cleavage site for cathepsin B, facilitating the release of the cytotoxic agent upon entry into targeted cells. Rolinsatamab talirine is primarily utilized in therapeutic applications where precise delivery of cytotoxic agents to cells expressing PRLR is required.

Cat. No.

AT1350

CAS No.

2845128-03-0

Imelciment

Imelciment is a human monoclonal antibody of the half-IgG4 subtype, featuring a kappa light chain and engineered hinge regions (h-CH2-CH3). Specifically designed to target NPR1 (Natriuretic Peptide Receptor 1), this antibody is optimized for high specificity and stability, making it a valuable tool for research into cardiovascular signaling pathways and potential therapeutic applications.

Cat. No.

AT1391

CAS No.

2097125-54-5

Garetosmab

Synonyms: REGN 2477

Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody designed to selectively inhibit activin A. This specificity makes it an ideal tool for investigating fibrodysplasia ossificans progressiva (FOP), providing valuable insights into the pathophysiology of this rare and debilitating condition. Garetosmab's targeted action on activin A opens avenues for exploring therapeutic interventions in FOP research.